Summary
Intuitive Surgical, Inc. (ISRG) reported strong financial results for the second quarter and the first six months of 2019, demonstrating robust growth across its key revenue streams and operational segments. Total revenue increased by 21% year-over-year to $1,098.9 million for the quarter and 17% to $2,072.6 million for the six-month period. This growth was primarily driven by a 22% increase in instrument and accessory revenue, a 24% increase in systems revenue, and a 13% increase in service revenue for the quarter. The company also saw a significant increase in da Vinci Surgical System shipments, up 24% year-over-year for the quarter, contributing to a 13% increase in the installed base. Operating income saw a substantial 29% increase for the quarter, reaching $359.0 million. The company maintains a strong liquidity position with over $5.1 billion in cash, cash equivalents, and investments as of June 30, 2019. Looking ahead, Intuitive Surgical is actively investing in research and development, with R&D expenses increasing by 27% for the quarter to support new product initiatives like the Ion endoluminal system and the da Vinci SP Surgical System. The company also announced a pending acquisition of certain assets from Schölly Fiberoptic, signaling strategic expansion. While the company faces ongoing legal matters, including patent litigation, its core business demonstrates sustained demand and growth, supported by increasing procedure volumes and strategic product development.
Financial Highlights
46 data points| Revenue | $1.10B |
| Cost of Revenue | $339.90M |
| Gross Profit | $759.00M |
| R&D Expenses | $120.80M |
| SG&A Expenses | $279.20M |
| Operating Expenses | $400.00M |
| Operating Income | $359.00M |
| Net Income | $318.30M |
| EPS (Basic) | $0.92 |
| EPS (Diluted) | $0.89 |
| Shares Outstanding (Basic) | 346.20M |
| Shares Outstanding (Diluted) | 357.90M |
Key Highlights
- 1Total revenue grew by 21% year-over-year to $1,098.9 million in Q2 2019.
- 2Instrument and accessory revenue increased by 22%, driven by a 17% rise in da Vinci procedures.
- 3Systems revenue grew by 24% to $343.8 million, with total system shipments up 24% to 273 units.
- 4The installed base of da Vinci Surgical Systems reached approximately 5,270 units, a 13% increase year-over-year.
- 5Operating income rose by 29% to $359.0 million in Q2 2019.
- 6Research and Development expenses increased by 27% to $120.8 million, reflecting investment in new products.
- 7The company ended the quarter with $5.1 billion in cash, cash equivalents, and investments, indicating a strong liquidity position.